Although the media blitz will tell you of the great benefits of this toxic chemical, please read the fine print before poisoning yourself for minimal gain.
The “Jupiter” trial was funded by Astra Zeneca (the maker of the drug being tested) to study primary prevention of cardiovascular disease (fatal and nonfatal) in healthy patients with low LDL (<130) yet elevated C reactive protiens (>2.0).
Patients were randomized to receive either rosuvastatin (Crestor) 20mg daily or placebo. After 1.9 years, LDL dropped by 50% and C reactive protiens by 37% in patients on rosuvastatin. In all there were 198 deaths out of 8901 rosuvastatin patients and 247 deaths out of 8901 patients on placebo.
From examination of table 3 of the study (not included here) if you subtract “not fatal myocardial infarction” from “any myocardial infarction,” you find out that there were 9 myocardial infarction (MI) deaths in the rosuvastatin arm and only 6 in the placebo arm. That shows a 50% increase in MI deaths in the arm taking Crestor.
- there were 51 more subjects in the placebo arm than in the Rosuvastatin reporting a family history of coronary heart disease.
- At the start of the study 71 more subjects in the placebo arm than in the Rosuvastatin arm had metabolic syndrome.
- By the end of the study only 75% of subjects had remained compliant. By not reporting which arm of the study the dropouts were from makes any interpretation of adverse reaction inconclusive.
- Myopathies were reported to be about equal, which is a highly suspect finding.
Therefore, for every 83 people treated for 1.9 years 1 will benefit. At $3.50 per dose, it would COST $201,000 to benefit that 1 person, not including the additional expenses suffering and deaths incurred from the increased number of patients with statin-induced diabetes.